Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease

被引：44

作者：

Buerger, K

Otto, M

Teipel, SJ

Zinkowski, R

Blennow, K

DeBernardis, J

Kerkman, D

Schröder, J

Schönknecht, P

Cepek, L

McCulloch, C

Möller, HJ

Wiltfang, J

Kretzschmar, H

Hampel, H

机构：

[1] Univ Munich, Dementia Res Sect, D-80336 Munich, Germany

[2] Univ Munich, Alzheimer Mem Ctr, Memory Clin, D-80336 Munich, Germany

[3] Univ Munich, Geriatr Psychiat Branch, Dept Psychiat, D-80336 Munich, Germany

[4] Univ Gottingen, Dept Neurol, D-37075 Gottingen, Germany

[5] Appl NeuroSolut Inc, Vernon Hills, IL 60061 USA

[6] Univ Gothenburg, Sahlgrens Univ Hosp, Dept Clin Neurosci, Unit Neurochem, Molndal, Sweden

[7] Heidelberg Univ, Sect Gerontopsychiat, D-69115 Heidelberg, Germany

[8] Univ Erlangen Nurnberg, Dept Psychiat, D-91054 Erlangen, Germany

[9] Univ Munich, Inst Neuropathol, D-81377 Munich, Germany

来源：

NEUROBIOLOGY OF AGING | 2006年 / 27卷 / 01期

关键词：

Creutzfeldt-Jakob disease (CJD); Alzheimer's disease (AD); diagnosis; differential diagnosis; cerebrospinal fluid (CSF); biological marker; tau protein; phosphorylated tau protein;

D O I：

10.1016/j.neurobiolaging.2004.12.003

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

To study the potential diagnostic value of abnormally phosphorylated tau protein in Creutzfeldt-Jakob disease (CJD) compared to Alzheimer's disease (AD), we determined levels of tau phosphorylated at threonine 231 (p-tau(231)) and of total tau (t-tau) in cerebrospinal fluid (CSF) of CJD patients, AD patients, and healthy controls (HQ. CID patients showed excessively high t-tau levels but relatively low p-tau(231) concentrations compared to the AD group. t-tau alone yielded the best diagnostic accuracy to differentiate between CID and AD patients, when compared to p-tau(231) and the p-tau(231)/t-tau ratio (97, 78, and 95% correctly allocated cases, respectively). Our findings indicate a dissociation in the direction of change in CSF levels of t-tau and p-tau(231) in CID when compared to AD. (C) 2005 Elsevier Inc. All rights reserved.

引用

页码：10 / 15

页数：6

共 23 条

[1] CSF markers for incipient Alzheimer's disease [J].

Blennow, K ;

Hampel, H .

LANCET NEUROLOGY, 2003, 2 (10) :605-613

[2] Differentiation of geriatric major depression from Alzheimer's disease with CSF tau protein phosphorylated at threonine 231 [J].

Buerger, K ;

Zinkowski, R ;

Teipel, SJ ;

Arai, H ;

DeBernardis, J ;

Kerkman, D ;

McCulloch, C ;

Padberg, F ;

Faltraco, F ;

Goernitz, A ;

Tapiola, T ;

Rapoport, SI ;

Pirttilä, T ;

Möller, HJ ;

Hampel, H .

AMERICAN JOURNAL OF PSYCHIATRY, 2003, 160 (02) :376-379

[3] Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 [J].

Buerger, K ;

Zinkowski, R ;

Teipel, SJ ;

Tapiola, T ;

Arai, H ;

Blennow, K ;

Andreasen, N ;

Hofmann-Kiefer, K ;

DeBernardis, J ;

Kerkman, D ;

McCulloch, C ;

Kohnken, R ;

Padberg, F ;

Pirttilä, T ;

Schapiro, MB ;

Rapoport, SI ;

Möller, HJ ;

Davies, P ;

Hampel, H .

ARCHIVES OF NEUROLOGY, 2002, 59 (08) :1267-1272

[4] CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects [J].

Buerger, K ;

Teipel, SJ ;

Zinkowski, R ;

Blennow, K ;

Arai, H ;

Engel, R ;

Hofmann-Kiefer, K ;

McCulloch, C ;

Ptok, U ;

Heun, R ;

Andreasen, N ;

DeBernardis, J ;

Kerkman, D ;

Moeller, HJ ;

Davies, P ;

Hampel, H .

NEUROLOGY, 2002, 59 (04) :627-629

[5] Biological markers for therapeutic trials in Alzheimer's disease - Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease [J].

Frank, RA ;

Galasko, D ;

Hampel, H ;

Hardy, J ;

de Leon, MJ ;

Mehta, PD ;

Rogers, J ;

Siemers, E ;

Trojanowski, JQ .

NEUROBIOLOGY OF AGING, 2003, 24 (04) :521-536

[6] Coexistence of Alzheimer-type neuropathology in Creutzfeldt-Jakob disease [J].

Hainfellner, JA ;

Wanschitz, J ;

Jellinger, K ;

Liberski, PP ;

Gullotta, F ;

Budka, H .

ACTA NEUROPATHOLOGICA, 1998, 96 (02) :116-122

[7] Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease -: A comparative cerebrospinal fluid study [J].

Hampel, H ;

Buerger, K ;

Zinkowski, R ;

Teipel, SJ ;

Goernitz, A ;

Andreasen, N ;

Sjoegren, M ;

DeBernardis, J ;

Kerkman, D ;

Ishiguro, K ;

Ohno, H ;

Vanmechelen, E ;

Vanderstichele, H ;

McCulloch, C ;

Möller, HJ ;

Davies, P ;

Blennow, K .

ARCHIVES OF GENERAL PSYCHIATRY, 2004, 61 (01) :95-102

[8] Advances in the development of biomarkers for Alzheimer's disease:: from CSF total tau and Aβ1-42 proteins to phosphorylated tau protein [J].

Hampel, H ;

Goernitz, A ;

Buerger, K .

BRAIN RESEARCH BULLETIN, 2003, 61 (03) :243-253

[9] A METHOD OF COMPARING THE AREAS UNDER RECEIVER OPERATING CHARACTERISTIC CURVES DERIVED FROM THE SAME CASES [J].

HANLEY, JA ;

MCNEIL, BJ .

RADIOLOGY, 1983, 148 (03) :839-843

[10] Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease [J].

Itoh, N ;

Arai, H ;

Urakami, K ;

Ishiguro, K ;

Ohno, H ;

Hampel, H ;

Buerger, K ;

Wiltfang, J ;

Otto, M ;

Kretzschmar, H ;

Moeller, HJ ;

Imagawa, M ;

Kohno, H ;

Nakashima, K ;

Kuzuhara, S ;

Sasaki, H ;

Imahori, K .

ANNALS OF NEUROLOGY, 2001, 50 (02) :150-156

← 1 2 3 →